Kelly, Ronan J. http://orcid.org/0000-0002-6446-2103
Landon, Blair V. http://orcid.org/0000-0002-5235-7410
Zaidi, Ali H. http://orcid.org/0000-0002-5463-2252
Singh, Dipika
Canzoniero, Jenna V.
Balan, Archana
Hales, Russell K.
Voong, K. Ranh
Battafarano, Richard J.
Jobe, Blair A.
Yang, Stephen C.
Broderick, Stephen
Ha, Jinny
Marrone, Kristen A.
Pereira, Gavin
Rao, Nisha http://orcid.org/0009-0003-6833-1922
Borole, Aryan
Karaindrou, Katerina
Belcaid, Zineb
White, James R.
Ke, Suqi
Amjad, Ali I.
Weksler, Benny
Shin, Eun Ji
Thompson, Elizabeth
Smith, Kellie N. http://orcid.org/0000-0002-6295-8930
Pardoll, Drew M. http://orcid.org/0000-0001-6215-1013
Hu, Chen http://orcid.org/0000-0003-4672-1981
Feliciano, Josephine L.
Anagnostou, Valsamo http://orcid.org/0000-0001-9480-3047
Lam, Vincent K. http://orcid.org/0000-0002-1319-2588
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA121113, UG1CA233259, R37 CA251447)
Cancer Research Institute
Conquer Cancer Foundation
Article History
Received: 5 June 2023
Accepted: 16 February 2024
First Online: 19 March 2024
Competing interests
: R.J.K. reports receiving advisory board/consulting fees from Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, EMD Serono, Exact Sciences, Grail, Ipsen, Merck, Novartis, Novocure, Phillips, Takeda, Toray and grant support paid to Johns Hopkins University and Baylor University Medical Center from Bristol Myers Squibb and Eli Lilly. E.J.S. is a consultant for Boston Scientific. A.H.Z. has served in a consultant/advisory role for Previse, has received research funding from Eli Lilly, Prognomiq, BilliontoOne, Genece Health and Tempus and has equity interest in Previse, Tg Therapeutics and Gritstone Bio. K.A.M. is a consultant for AstraZeneca, Amgen, Puma Biotechnology, Jannsen, Mirati Therapeutics, Daiichi Sankyo/Lilly and Regeneron and receives research funding from Mirati, Bristol Myers Squibb and AstraZeneca. K.N.S. has received honoraria from Illumina and Adaptive Biotechnologies, research funding to Johns Hopkins University from Bristol Myers Squibb, AstraZeneca and Abbvie, is an inventor on a patent application related to the MANAFEST technology described herein (16/341,862) that has been licensed to one or more entities and owns founder’s equity in ManaT Bio. J.L.F. has served in a consultant/advisory role for Genentech, Eli Lilly, AstraZeneca, Merck, Takeda, Coherus, Regeneron and Pfizer and has received research funding (directly to the institution) from AstraZeneca, Pfizer and Bristol Myers Squibb. V.L. has served in a consultant/advisory role for Anheart Therapeutics, Takeda, Seattle Genetics, Bristol Myers Squibb, AstraZeneca and Guardant Health and has received research funding from GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca, Merck and Seattle Genetics. V.A. receives research funding to Johns Hopkins University from AstraZeneca and Personal Genome Diagnostics, has received research funding to Johns Hopkins University from Bristol Myers Squibb and Delfi Diagnostics in the past 5 years, is an advisory board member for AstraZeneca and Neogenomics and receives honoraria from Foundation Medicine and Personal Genome Diagnostics. V.A. is an inventor on patent applications (63/276,525, 17/779,936, 16/312,152, 16/341,862, 17/047,006 and 17/598,690) submitted by Johns Hopkins University related to cancer genomic analyses, ctDNA therapeutic response monitoring and immunogenomic features of response to immunotherapy that has been licensed to one or more entities. Under the terms of these license agreements, the University and inventors are entitled to fees and royalty distributions. The other authors declare no competing interests.